ThromboGenics and Rhein Minapharm Announce Agreement for Next-Generation Thrombolytic Agent
Agreement Covers Development and Commercialization of Novel Heart Attack Treatment in Middle East and Africa
16-Oct-2007 -
ThromboGenics NV and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE jointly announced that they have completed a license agreement for the production, clinical development and commercialization of ThromboGenics' THR-174, the next-generation derivative of Staphylokinase, in the Middle ...
acute myocardial infarction
allergic reactions
license agreements
+5